Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – 9,10-seco- cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2007-01-16
2007-01-16
Hui, San-Ming (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
9,10-seco- cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
active
10369752
ABSTRACT:
To obtain a treating agent for Paget's disease of bone, there is provided a method of inhibiting expression of general transcription factor of steroid hormone receptor.
REFERENCES:
patent: 4857518 (1989-08-01), DeLuca et al.
patent: 5583125 (1996-12-01), Steinmeyer et al.
patent: 5719297 (1998-02-01), Tabe et al.
patent: 197 10 054 (1998-09-01), None
patent: 197 44 127 (1999-04-01), None
patent: 1 123 921 (2001-08-01), None
patent: WO 02/15894 (2002-02-01), None
Thavarajah et al., Biochemical and Biophysical Research Communications, 1990 ;171(3) :1056-1063.
S.D. Neale, et al., “Osteoclast Differentiation From Circulating Mononuclear Precursors in Paget's Disease Is Hypersensitive to 1,25-Dihydroxyvitamin D3and RANKL,” Bone, Sep. 2000, pp. 409-416, vol. 27, No. 3, Pergamon Press, Oxford, GB.
D. Somjen, et al., “A non-calcemic analog of 1α,25 dihydroxy vitamin D3(JKF) upregulates the induction of creatine kinase B by 17β estradiol in osteoblast-like ROS 17/2.8 cells and in rat diaphysis,” The Journal of Steroid Biochemistry & Molecular Biology, Jun. 2001, pp. 205-212, vol. 77, No. 4/5, Elsevier Science Ltds., Oxford, GB.
Andrea Toell, et al., “Different Molecular Mechanisms of Vitamin D3Receptor Antagonists,” Molecular Pharmacology, 2001, pp. 1478-1485, vol. 59, No. 6.
Michaela Herdick, et al., “Antagonistic Action of a 25-Carboxylic Ester Analogue of 1α,25-Dihydroxyvitamin D3Is Mediated by a Lack of Ligand-induced Vitamin D Receptor Interaction with Coactivators,” The Journal of Biological Chemistry, Jun. 2, 2000, pp. 16506-16512, vol. 275, No. 22.
Yvonne Bury, et al., “Structure Activity Relationship of Carboxylic Ester Antagonists of the Vitamin D3Receptor,” Molecular Pharmacology, Nov. 2000, pp. 1067-1074, vol. 58, No. 5.
Michaela Herdick, “Carboxylic ester antagonists of 1α,25-dihydroxyvitamin D3show cell-specific actions,” Chemistry & Biology, 2000, pp. 885-894, vol. 7, No. 11.
Tanja Gaschott, “Butyrate-Induced Differentiation of Caco-2 Cells Is Mediated by Vitamin D. Receptor,” Biochemical and Biophysical Research Communications, 2001, pp. 690-696, vol. 288, No. 3, Academic Press, Inc., Orlando, Florida.
T. Suda, “Modulation of Osteoclast Differentiation by Local Factors,” Bone, Aug. 1, 1995, pp. 87S-91S, vol. 2, No. 17, Pergamon Press, Oxford, GB.
S. Patel, et al., “Drugs Used in the Treatment of Metabolic Bone Disease Clinical Pharmacology and Therapeutic Use,” Adis International Limited, 1993, pp. 594-617, vol. 46, No. 4.
N. Kurihara, et al., “Identification of Committed Mononuclear Precursors for Osteoclast-Like Cells Formed in Long Term Human Marrow Cultures”, Endocrinology, vol. 126, No. 5, pp. 2733-2741.
Rowena D. Devlin, et al., “Alterations in Vitamin D Metabolites During Treatment of Paget's Disease of Bone with Calcitonin or Etidronate”, Journal of Bone and Mineral Research, vol. 5, No. 11, 1990, pp. 1121-1126.
Noriyoshi Kurihara, et al., “Osteoclasts expressing the measles virus nucleocapsid gene display a pagetic phenotype”, The Journal of Clinical Investigation, Mar. 2000, vol. 105, No. 5, pp. 607-614.
Gabrielle Mengus, et a., “Cloning and characterization of hTAFII18, hTAFII20 and hTAFII28: three subunits of the human transcription factor TFIID”, The EMBO Journal, 1995, vol. 14, No. 7, pp. 1520-1531.
Michaela Herdick, et al., “Antagonistic Action of a 25-Carboxylic Ester Analogue of 1α,25-Dihydroxyvitamin D3Is Mediated by a Lack of Ligand-induced Vitamin D Receptor Interaction with Coactivators”, The Journal of Biological Chemistry, Jun. 2, 2000, vol. 275, No. 22, pp. 16506-16512.
Rowena A. Devlin, et al., “Long-Term Elevation of 1,25-Dihydroxyvitamin D After Short-Term Intravenous Administration of Pamidronate (Aminohydroxypropylidene bisphosphonate, APD) in Paget's Disease of Bone”, Journal of Bone and Mineral Research, 1994, vol. 9, No. 1, pp. 81-85.
Cheikh MenaA, et al., “I,25-Dihydroxyvitamin D3Hypersensitivity of Osteoclast Precursors from Patients with Paget's Disease”, Journal of Bone and Mineral Research, No. 2, 2000, vol. 15, pp. 228-236.
Ethel S. Siris, “Paget's Disease of Bone”, Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, Department of Medicine, The University of Chicago Medical Center, Chapter 77, pp. 415-425.
Daishiro Miura, et al., “Antagonistic Action of Novel 1α,25-Dihydroxyvitamin D3-26,23-lactone Analogs on Differentiation of Human Leukemia Cells (HL-60) Induced by 1α,25-Dihydroxyvitamin D3”, The Journal of Biological Chemistry, Jun. 4, 1999, vol. 274, No. 23, pp. 16392-16399.
Keiichi Ozono, et al., Analysis of the Molecular Mechanism for the Antagonistic Action of a Novel 1α,25-Dihydroxyvitamin D3Analogue toward Vitamin D Receptor Function , The Journal of Biological Chemistry. Nov. 5, 1999. vol. 274, No. 45, pp. 32376-32381.
Yamada et al., Steroids, 2001 ; 66: 177-187.
Imaizumi Atsushi
Ishizuka Seiichi
Kurihara Noriyoshi
Oue Yasuhiro
Reddy Sakamuri V.
Hui San-Ming
Teijin Limited
LandOfFree
Treating agent for Paget's disease of bone does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treating agent for Paget's disease of bone, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treating agent for Paget's disease of bone will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3752152